Welcome and Comments

Call to Order

Drug Utilization Review (DUR) Board Report

Magellan Medicaid Administration Update

Approval of Minutes from October 20, 2016 Meeting

PDL Management

- Potential New Therapeutic Classes (PDL Category)
  - Long-Acting Reversible Contraceptives (LARCS) (Contraceptives)
  - Long-Acting Injectable Antipsychotics (Antipsychotics)
  - Antiparasitics (Dermatologic Agents Topical)
  - Agents to treat Rosacea (Dermatologic Agents Topical)

- PDL Phase I – New Drug Review (Therapeutic Class)
  - Brand Drugs
    - Epaned® Solution (New Dosage Form) (Angiotensin Modulators)
    - Emflaza® (Glucocorticoids, Oral)
    - Eucrisa® (Immunomodulators, Atopic Dermatitis)
    - Bromsite® (Ophthalmics, Anti-Inflammatories)
    - Micort-HC® (Topical Steroids)
  - Generics Drugs
    - Olmesartan/HCTZ (generic Benicar® HCT), olmesartan (generic Benicar®) (Angiotensin Modulators)
    - Amlodipine/olmesartan/HCTZ (generic Tribenzor®) & amlodipine/olmesartan (generic Azor®) (Angiotensin Modulators Combinations)
    - Aprepitant capsule/pack (generic Emend®) (Antiemetic/Antivertigo Agents)
    - Quetiapine fumarate ER (generic Seroquel® XR) (Antipsychotics)
    - Metoprolol XL/HCTZ (generic Dutoprol® XL) (Beta Blockers)
    - Levalbuterol tartrate HFA (generic Xopenex® HFA) (Bronchodilators, Beta-Agonist)
    - Epinephrine (generic EpiPen® and EpiPen® Jr.) (Epinephrine, Self-Injected)
    - Prednisolone sodium phosphate solution (generic Millipred™) & prednisolone sodium phosphate solution (generic Veripred™) (Glucocorticoids, Oral)
    - Ezetimibe (generic Zetia®) (Lipotropics, Other)
    - Flurandrenolide (generic Cordran®) (Topical Steroids)

- PDL Phase II – Annual Review
  - Therapeutic Classes with Updates
    - Analgesics
      - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (includes Cox-2 inhibitors and topical agents)
      - Opiate Dependence Treatments
      - Opioids: Long Acting
• **PDL Phase II – Annual Review (continued)**
  
  o **Antibiotics/Anti-Infectives**
    - Cephalosporins *(Second and Third Generations)*
    - Quinolones *(Second and Third Generations)*
  
  o **Antivirals (oral)**
    - Antivirals for Herpes (HSV)
    - Antivirals for Influenza
  
  o **Blood Modifiers**
    - Antihyperuricemics
  
  o **Cardiac Medications**
    - Anticoagulants *(includes oral agents, low molecular weight heparins and Factor XA Inhibitors)*
    - Platelet Aggregation Inhibitors
  
  o **Central Nervous System**
    - Antihyperkinesis/CNS Stimulants
    - Non-Ergot Dopamine Receptor Agonists
    - Neuropathic Pain
    - Skeletal Muscle Relaxants
    - Smoking Cessation Agents
  
  o **Dermatologic Agents (Topical)**
    - Acne Agents *(includes benzoyl peroxide, clindamycin, retinoids & combinations)*
    - Antifungal Agents
  
  o **Endocrine and Metabolic Agents**
    - Androgenic Agents
    - Bone Resorption Suppression and Related Agents *(includes bisphosphonates, calcitonins and others)*
    - Hypoglycemics: Alpha-Glucosidase Inhibitors
    - Hypoglycemics: Incretin-Mimetics/Enhancers *(includes DPPIV)*
    - Hypoglycemics: Insulins *(including combination agents)*
    - Hypoglycemics: Meglitinides
    - Hypoglycemics: Metformins
    - Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
    - Hypoglycemics: Sulfonylureas
    - Hypoglycemics: Thiazolidinediones
    - Progestational Agents
  
  o **Immunologic Agents**
    - Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate *(all indications)*

**Therapeutic Classes Without Updates (reviewed by the Department)**

o **Analgesics**
  - Opioids: Short Acting
  - Antimigraine Agents, Triptans

o **Antibiotics/Anti-Infectives**
  - Antibiotics, GI
  - Antibiotics, Topical
  - Antifungals, Oral
  - Macrolides & Ketolides
  - Otic Antibiotics
PDL Phase II – Annual Review (continued)
  o Blood Modifiers
    ▪ Erythropoiesis Stimulating Proteins
  o Central Nervous System
    ▪ Multiple Sclerosis Agents
  o Dermatologic Agents (Topical)
    ▪ Antivirals (Herpes HSV)
    ▪ Psoriasis Agents
  o Endocrine and Metabolic Agents
    ▪ Estrogens (vaginal and oral)
    ▪ Pancreatic Enzymes

Confidential Meeting (Pricing Information Discussion) P&T Committee Members & DMAS Staff
Criteria Discussion of Phase I New Drugs P&T Committee Members
Criteria Discussion of Phase II Drugs P&T Committee Members
Next Meeting – October 19, 2017 (tentative) Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on only the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

  • PDL Phase II Annual Review – April 2016 to present
  • New Drugs in PDL Phase I Drug Classes – April 2015 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Wednesday, March 22, 2017.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST Wednesday, March 22, 2017.